Axsome Therapeutics

AXSM Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$168.50

-1.91% today

52W: $86.99 – $191.50

52W Low: $86.99 Position: 78% 52W High: $191.50

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

27.7x

Forward Price/Earnings

P/S Ratio

13.5x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$8.6B

Market Capitalization

Revenue Growth

65%

YoY Revenue Growth

Profit Margin

-28.69%

Net profit margin

ROE

-252.12%

Return on Equity

Beta

0.47

Market sensitivity

Short Interest

6.41%

% of float sold short

Avg. Volume

633,150

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

21 analysts

Avg. Price Target

$223.66

+32.73% upside

Target Range

$198.82 – $260.00

About the Company

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 925 Exchange: NGM